Shanghai Haoyuan Chemexpress Co. Ltd. A

Haoyuan Pharmaceutical disclosed its semi-annual report on August 26, achieving operating revenue of 1.648 billion yuan in the first half of 2026, up 25.71% year-on-year; net profit attributable to shareholders of the listed company was 171 million yuan, up 12.81% year-on-year; basic earnings per share were 0.81 yuan. The company plans to distribute a cash dividend of 0.9 yuan per 10 shares, tax included.

Haoyuan Pharmaceutical announced on August 26 that it plans to distribute a cash dividend of 0.9 yuan, tax included, for every 10 shares to all shareholders. The total payout is expected to be 19.19 million yuan, accounting for 11.21% of the net profit attributable to the parent company for the first half of 2026. In the interim period of 2026, the company achieved revenue of 1.648 billion yuan and net profit attributable to the parent company of 171 million yuan.

Haoyuan Pharmaceutical released its 2026 semi-annual report on the evening of August 26. In the first half of the year, it achieved attributable net profit of approximately 171 million yuan, a year-on-year increase of 12.81%. During the reporting period, the company achieved operating revenue of approximately 1.648 billion yuan, a year-on-year increase of 25.71%. Among this, revenue from the front-end life science reagents business was approximately 1.212 billion yuan, up 34.03% year-on-year; revenue from specialty active pharmaceutical ingredients, intermediates, and formulations was approximately 425 million yuan, up 6.45% year-on-year. The company's main businesses include research and development of life science reagents in the drug discovery field, as well as drug research and development, process optimization, and commercial production of active pharmaceutical ingredients, intermediates, starting materials, and formulations.

Haoyuan Pharmaceutical announced that its wholly-owned subsidiary, Yaoyuan Biotech Qidong Co., Ltd., passed a U.S. FDA pre-approval inspection with zero deficiencies. The subsidiary underwent the inspection from June 22 to 26, 2026, and recently received the on-site inspection report confirming the result. This marks the first time its finished dosage manufacturing site has passed a U.S. FDA inspection, which will help the company expand in the U.S. market and have a positive impact on its operating performance and international competitiveness.

The Sci-Tech Innovation Board Medical ETF Huaxia, ticker 588130, saw its latest shares reach 456 million, a one-year high. As of 2:07 PM on July 29, 2026, the ETF rose 0.91 percent, with the latest price at 1 yuan, intraday turnover rate of 13.39 percent, and trading volume of 60.8075 million yuan. The Shanghai Sci-Tech Innovation Board Biomedical Index it tracks surged 1.19 percent, with constituent stock Haoyuan Chemexpress rising 9.32 percent and Baili Tianheng rising 4.87 percent. In related news, the 2026 government work report for the first time explicitly designated biomedicine as an emerging pillar industry. The 15th Five-Year Plan listed brain-computer interfaces as a frontier core industry. The leap in top-level policy positioning, combined with China's innovative drug license-out deals hitting a record high and the first prescription for the implantable brain-computer interface NEO, marks the track's transition from the laboratory to clinical application.